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Abstract
Background: Intravesical immunotherapy with Mycobacterium bovis bacillus Calmette-Guérin has been established as 
the most effective adjuvant treatment for high risk non-muscle-invasive bladder cancer (NMIBC). We investigated the 
differences between the S4-Jena BCG strain and commercially available BCG strains. We tested the genotypic varieties 
between S4-Jena and other BCG strains and analysed the effect of the BCG strains TICE and S4-Jena on two bladder 
cancer cell lines.
Results: In contrast to commercially available BCG strains the S4-Jena strain shows genotypic differences. 
Spoligotyping verifies the S4-Jena strain as a BCG strain. Infection with viable S4-Jena or TICE decreased proliferation in 
the T24 cell line. Additionally, hallmarks of apoptosis were detectable. In contrast, Cal29 cells showed only a slightly 
decreased proliferation with TICE. Cal29 cells infected with S4-Jena, though, showed a significantly decreased 
proliferation in contrast to TICE. Concordantly with these results, infection with TICE had no effect on the morphology 
and hallmarks of apoptosis of Cal29 cells. However, S4-Jena strain led to clearly visible morphological changes and 
caspases 3/7 activation and PS flip.
Conclusions: S4-Jena strain has a direct influence on bladder cancer cell lines as shown by inhibition of cell 
proliferation and induction of apoptosis. The data implicate that the T24 cells are responder for S4-Jena and TICE BCG. 
However, the Cal29 cells are only responder for S4-Jena and they are non-responder for TICE BCG. S4-Jena strain may 
represent an effective therapeutic agent for NMIBC.
1. Background
In non-muscle-invasive bladder cancer (NMIBC) patients
with a high-risk for recurrence an immediate chemother-
apy should be followed by adjuvant therapy with Myco-
bacterium bovis bacillus Calmette-Guerin (BCG) [1]. The
mechanism by which BCG is effective in the treatment of
bladder cancer remains still controversially discussed,
yet. BCG therapy results finally in a local immune
response characterised by cytokine expression of bladder
cells [2]. In addition, influx of granulocytes and mononu-
clear cells into bladder wall has been observed [3]. Several
studies indicate a high survival rate and persistence of
BCG in the bladder wall after intravesical BCG-treatment
[4,5]. Several in vitro studies demonstrated a direct effect
of BCG on bladder cancer cell lines in the absence of
immune mechanisms [6]. These effects included cell
cycle arrest [7], inhibition of cell proliferation [8-10] as
well as apoptosis [11]. The BCG strain applied for
NMBIC therapy showed different effects on bladder can-
cer cell lines.
History of S4-Jena
The BCG strain S4-Jena applied in this study was brought
from Gothenburg to Jena in 1950. In contrast to vaccines
prepared from other BCG strains, S4-Jena showed no sig-
nificant side effects such as systemic infections in neo-
nates [12]. The S4-Jena strain was introduced into a
multicentre clinical trial for intravesical adjuvant therapy
of bladder cancer from 1988-1991 in 7 hospitals. 217
patients with a tumour stage TaG1-2/T1G1-3 were
included. Recurrence-free survival was defined as the
time from initial transurethral resection to either recur-
rence of the tumour. It was shown that 80.2% of the
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patients had no recurrence within the follow-up period
(16.4 months). Side effects like dysuria (41.9%), a conspic-
uous pathological urinary-status (31.8%) and fever
(16.1%) were reported. Based on this study the S4-Jena
strain was licensed for bladder cancer therapy in east
Europe in 1990.
Regarding the results of this study we focussed in this
work on the difference between the S4-Jena BCG strain
and commercially available BCG strains. Additionally, we
investigated the effects of S4-Jena strain on bladder can-
cer cell lines in comparison to TICE strain.
2. Methods
2.1 Propagation of strain
The S4-Jena strain was propagated and harvested by the
original method published by Berger in 1953 [13]. The
BCG strain S4-Jena was typed via spoligotyping [14] as a
Mycobacterium bovis ssp. Bacilli Calmette Guerin by the
National Reference Centre (NRC) for Mycobacteria  in
Borstel, Germany. The commercially produced BCG
strains TICE (Apogepha, Germany), RIVM (Medac, Ger-
many) and Connaught (Cytochemia, Germany) were
available as lyophilisates. All BCG strains were used in a
concentration of 2 × 108bacteria/ml.
2.2 Cell lines
Two human bladder cancer cell lines T24 (ACC376) and
Cal29 (ACC515), obtained from German Collection of
Microorganisms and Cell Cultures (DSMZ, Germany)
were used in this study. Cell lines were cultured as mono-
layer in D-MEM medium (GIBCO, Germany) supple-
mented with 10% foetal bovine serum (GIBCO,
Germany) at 37°C in an atmosphere with 5%CO2.
2.3 Pulsed-field gel electrophoresis (PFGE)
DNA preparation was performed as described previously
b y  S l u t s k y  e t  a l ,  w e  u s e d  V s p I  a s  r e s t r i c t i o n  e n z y m e
(HYBAID, Germany) [15]. In short, PFGE (CHEF-DR®II,
BIO-RAD Lab., USA) was performed in 1% agarose for 22
h at 6 V/cm, pulse times 1-40 s, temperature 15°C. The
PFGE pattern was stained with 0.5 μg/ml ethidium bro-
mide (Sigma-Aldrich, USA).
2.4 Cell proliferation assay
Cells (1×106/100 μl) were incubated at 37°C with 5% CO2
for 24 h. Then they were infected with 10 μl of a 1 × 108/
ml CFU BCG S4-Jena or TICE strain. Proliferation was
tested by a micro plate-based assay (WST-1, Roche, Ger-
many) that measures metabolic activity using tetrazolium
salts [16].
2.5 Scanning electron microscopy
Cells were seeded out on sterilized coverslips in 24-well
plates (1 × 106/ml), incubated at 37°C and 5%CO2 for 24 h
and infected with 100 μl of a 1 × 108/ml CFU S4-Jena and
TICE strains. After different incubation times (12 h and
24 h) the cells were fixed with 2.5% glutaraldehyde in 0.1
M sodium cacodylate buffer (pH 7.4) at room tempera-
ture (RT) for 30 min. Cells were dehydrated in rising eth-
anol concentrations followed by critical point drying and
gold sputter coating in a BAL-TEC-SCD-005 Sputter
Coater (BAL-TEC, Germany). The cells were examined
using a scanning electron microscope LEO-1450VP
(ZEISS, Germany) at 15 kV.
2.6 Apoptosis detection by laser scanning microscopy
Cells were seeded out in eight-well Lab-TekTM chamber
(1 × 104/ml), incubated at 37°C and 5% CO2 for 24 h and
infected with 10 μl of 1 × 108/ml CFU S4-Jena and TICE
strains. After 24 h infection time, cells were assayed for
phosphatidylserine (PS) using the Annexin V FITC-Kit
(Invitrogen, Germany). Afterwards, activated caspases-3/
7 was visualised using MagicRed™ (Immunochemistry,
USA). We used both tests according to manufacturer's
directions. The samples were observed under a fluores-
cence microscope LSM5 EXCITER (ZEISS, Germany).
2.7 Statistical analysis
Statistical analysis was performed using parametric
Mann-Whitney U-tests for data with a normal distribu-
tion. A value of p < 0.05 was considered as significant (*),
a value of p < 0.01 was considered as highly significant
(**). Data obtained are expressed as mean ± standard
deviation (SD).
Figure 1 Genotypic characterization of different BCG strains as 
analyzed by PFGE. Lane 1-2: RIVM strain, Lane 3-4: TICE strain, lane 5-
6: Connaught strain, 7-9: S4-Jena strain. Lane 10: λ ladder PFG Marker 
(BioLabs, Frankfurt, Germany).Schwarzer et al. Cancer Cell International 2010, 10:21
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3. Results
3.1 Genotypic characterisation of the BCG S4-Jena strain
Using pulsed-field gel electrophoresis we found geno-
typic varieties between the different BCG strains tested.
Genomic DNA was isolated from BCG strains RIVM,
TICE, Connaught Canada and S4-Jena. The results in
Fig.1 show the different DNA polymorphisms among the
kinships. The analysis of the S4-Jena strain showed a frag-
ment with a size of 267 kbp. In contrast, the TICE, RIVM
and Connaught strains did not show this fragment, but
two smaller ones of 203 kbp und 134 kbp size. However,
these both fragments were not detectable in the S4-Jena
strain.
3.2 Effect of BCG on the proliferation rate of bladder cancer 
cell lines
T24 and Cal29 cell lines showed different patterns of pro-
liferation after infection with viable BCG. Proliferation of
T24 cells decreased during the total incubation period
with S4-Jena or TICE (Fig.2A). Only 36% (TICE) and 29%
(S4-Jena) of the cells infected with BCG proliferated after
96 h compared to the uninfected control.
In contrast to T24, the Cal29 cells showed only a
slightly decreased proliferation of 84-98% compared to
the control between 1 h and 96 h after infection with
TICE strain (Fig.3A). Cells infected with S4-Jena, how-
ever, showed a significantly decreased proliferation (62-
77%) in contrast to TICE.
3.3 Effect of different BCG-strains on morphology of 
bladder cancer cell lines
A s  v i s u a l i s e d  b y  e l e c t r o n  m i c r o s c o p y  b o t h  t h e  T I C E
strain and the S4-Jena strain showed similar effects on
the T24 cells (Fig.2B-D). After 12 h the majority of cells
exhibited a rounded morphology and detached from the
base layer after infection with the strains compared to
untreated cells. Additionally, membrane blebbing
appeared on the surface of the cells. These effects were
Figure 2 A: Cell proliferation of T24 cells after infection with BCG S4-Jena and TICE. Proliferation was measured by WST-1. Results are reported 
as percentage inhibition of cell proliferation, where the optical density value from untreated cells was set as 100% of proliferation. Test was performed 
eight times by duplicate measurements. B-D: Effects of BCG strain S4-Jena and TICE on the cell membrane in T24 cells using scanning electron mi-
croscopy. Untreated T24 cells are showing a normal surface (B). Infection with TICE (C) and S4-Jena (D) strain led to morphological changes in the cells 
after 12 h.
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more pronounced after infection with S4-Jena than with
TICE BCG.
In contrast, the TICE infection had no effect on the
morphology of the Cal29 cells even after 24 h of culture.
Differing from TICE, the S4-Jena strain led to clearly visi-
ble morphological changes also in Cal29 cells even after
only 4 h (Fig.3B-D). Again, the infected cells adopted a
spherical shape, separated from the united cell structure,
and completely lost their adherence. Some cells formed
apoptotic membrane blebs. In some areas only cell frag-
ments were visible.
3.4 Apoptosis induction by BCG infection
We used different immunohistochemical tests to detect
apoptosis in bladder cancer cell lines after infection with
B C G .  A p o p t o s i s  i s  a  p h y s i o l o g i c a l  m o d e  o f  c e l l  d e a t h
defined by both morphological (e.g. nucleus fragmenta-
tion, apoptotic bodies) and biochemical criteria (e.g. acti-
vation of caspases). As shown in fig.4, fragmentation of
the nucleus (arrowhead) can be detected by staining with
Hoechst (blue) in T24 cell after infection with TICE (B)
as well as with BCG S4-Jena (C) after 24 h. Activated cas-
pases 3/7 could be shown after infection of T24 cells with
both strains. The exposure of PS on the plasma mem-
branes of T24 cells was induced after infection with both
strains. Furthermore, infection with S4-Jena led to a
lower number of adherent T24 cells, implicating that the
majority of cells had detached. In contrast, the Cal29 cells
showed only after infection with S4-Jena marginal cas-
pases 3/7 activation and exposure of PS on the plasma
membrane (fig.5 C). The infection of Cal29 cells with
TICE strain had no influence on caspases 3/7 or PS expo-
sure (fig.5 B).
4. Discussion
Intravesical installation of BCG as adjuvant treatment is
well established and has been part of routine treatment
for patients with superficial bladder cancer for more than
Figure 3 Cell proliferation of Cal29 cells after infection with BCG S4-Jena and TICE. Proliferation was measured by WST-1. Results are reported 
as percentage inhibition of cell proliferation, where the optical density value from untreated cells was set as 100% of proliferation. Test was performed 
eight times by duplicate measurements. B-D: Effects of BCG strain S4-Jena and TICE on the cell membrane in Cal29 cells using scanning electron mi-
croscopy. Untreated Cal29 cells are showing a normal surface (B). Cal29 cells treated with TICE strain for 12 h (C) show a similar appearance as untreat-
ed cells. Infection with S4-Jena strain led to morphological changes in the cells after 12 h (D).
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30 years [1,17,18]. The mechanisms by which BCG affects
the growth of superficial transitional bladder cancer are
still unclear. 30% of bladder cancers are BCG resistant
and the long-term durability of the response to BCG is
still limited [19]. For the present study we reactivated the
S4-Jena strain. We compared S4-Jena with BCG strains
which are commercially available for bladder cancer ther-
apy. Additionally, we analysed the effects of S4-Jena and
Tice on two different bladder tumour cell lines.
The genotypic varieties between different BCG strains
were tested. In this study we compared the commercially
available BCG strains RIVM, TICE, Connaught Canada
with the S4-Jena strain. Regarding the DNA polymor-
phisms a clear difference between S4-Jena and the other
strains was detectable. The restriction fragment pattern
differed in three bands. The S4-Jena strain showed a loss
of two bands (203 kbp und 134 kbp) in comparison to the
other strains due to the loss of a restriction site. This is
confirmed by the occurrence of a 267 kbp band that is not
present in the commercial strains. This is an evidence
that the S4-Jena strain belongs to the family of BCG
strains. Variations of two to three bands have been
observed in strains of some species when they are cul-
tured repeatedly over time [20]. These results agree with
the conclusion of Brosch et al, who classify the RIVM,
TICE and Connaught in a later BCG daughter strain
group (DU2 groupIV, Δint) characterized by a large num-
ber of deletions [21]. S4-Jena can be allocated in the early
DU2 group II, Δint, because it is derived from the Sweden
strain. This group shows a low number of deletions.
The second major aspect of this study was a functional
characterisation of S4-Jena as a potential agent for adju-
vant therapy. As the three commercially available BCG
strains are genetically closely related, only one strain was
used for further comparative experiments with the S4-
Jena strain. The TICE strain was chosen because it
belongs to the most comprehensively researched strains.
Many studies [3,22,23] assume that BCG infection causes
Figure 4 Apoptotic cell death in T24 cells infected with BCG. T24 cells were infected with BCG TICE (B) or S4-Jena (C) strain compared to uninfect-
ed control cells (A) for 24 h. Cells were stained with Annexin V (green), Caspases 3/7 (red) and Hoechst (blue). Arrowheads show nucleus fragmenta-
tion. Scale bars: 50 μm.
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a systemic immunological reaction. In the present study
we demonstrated that BCG bacteria even ha ve various
direct effects on two different bladder cancer cell lines
regarding proliferation and morphology.
A major difference between the two BCG strains was
seen in the reduction of cell proliferation. While TICE
only reduced proliferation in T24 cells, the S4-Jena strain
led to reduced proliferation in both cell-lines tested.
Sasaki et al showed a significant suppression of prolifera-
tion in T24 cells after infection with the Tokyo-172 strain
(DU2 groupI [21]) for 96 h and 120 h [9]. In comparison
to these data, in the present study inhibition of prolifera-
tion by 40-50% was detectable already after 24 h in T24
cell. Zhang et al described that the Connaught strain
(DU2 groupIV, Δint [21]) inhibits dose-dependently the
proliferation of bladder cancer cells of various grades [8].
Interestingly, the Connaught strain could also enhance
growth in the SD and RT4 cell lines. Rajala et al analysed
five BCG strains (Pasteur, Connaught, RIVM, TICE,
Evans) for cytostatic activity on bladder cancer cells [10].
They showed that BCG inhibited cell growth and this
effect was concentration-dependent in various strains
including TICE. In 120 h cultures the BCG strain TICE
has a slightly weaker cytostatic effect than the other four
strains. Pryor et al have also found that the Pasteur strain
exerts a direct, antiproliferative effect on bladder tumour
cells in the absence of immune mechanisms. The differ-
ences between the various studies may be due to the use
of different doses and strains of BCG and different cell
lines [6].
Our study clearly shows that the predominant effect of
BCG S4-Jena on the bladder cancer cell lines is a reduc-
tion of proliferation. In a similar pattern to the effect on
the proliferation TICE infection showed no morphologi-
cal effects on Cal29 cells, but on T24 cells. In contrast,
S4-Jena induced morphological changes in both cell lines.
The affected cells adopted distinct morphological
changes like spherical shape and cell membrane blebbing.
They separated from the united cell structure and com-
pletely lost their adherence. These are typical hallmarks
of apoptosis [24]. Chen et al demonstrated that the TICE
strain decreased the viability of bladder cancer cell lines,
Figure 5 Apoptotic cell death in Cal29 cells infected with BCG. Cal29 cells were infected with BCG TICE (B) or S4-Jena (C) strain compared to un-
infected control cells (A) for 24 h. Cells were stained with Annexin V (green), Caspases 3/7 (red) and Hoechst (blue). Scale bars: 50 μm.
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but did not induce apoptosis via DNA-laddering and cas-
pase-3 activation [7]. Sasaki et al indeed showed an inhi-
bition of proliferation in T24 cells by Tokyo-172 strain,
but also concluded that it was not mediated by apoptosis,
again employing DNA-laddering after 120 h of incuba-
tion [9]. Saitoh et al showed that Tokyo-172 significantly
decreased cell viability and induced apoptosis after 120 h
in both cell lines [11]. We expanded the methods for
apoptosis detection in T24 and Cal29 cells after infection
with TICE and S4-Jena strains by morphological features
like membrane blebbing and retraction from neighbour-
ing cells. In contrast to Chen et al we could detect cas-
pases 3/7 activation, fragmentation of nucleus and
additionally phosphatidylserin-flip after 24 h of BCG
infection in T24 cells [7]. The appearance of phosphati-
dylserine (PS) on the outer leaflet of the cell membrane is
one of the earliest indications of apoptosis [24]. In con-
trast, only S4-Jena but not TICE showed caspases 3/7
activation and PS flip in Cal29 cells supporting our prolif-
eration data. Thus we conclude that the inhibition of pro-
l i f e r a t i o n  i s  m e d i a t e d  b y  a n  i n d u c t i o n  o f  a p o p t o s i s .
Finally, the data implicate that the T24 cells are responder
for S4-Jena and TICE BCG. However, the Cal29 cells are
only responder for S4-Jena and they are non-responder
for TICE BCG.
5. Conclusion
Both tested strains act directly on tumour cells inhibiting
the proliferation in T24 cells. Since Cal29 cells were
affected by the S4-Jena strain but not by TICE, it can be
assumed that not all bladder tumours are susceptible to
every BCG strain. This indicates the need for evaluation
of susceptibility of bladder tumours to different BCG
strains before the adjuvant BCG therapy is initiated. The
S4-Jena strain is supposed to be an effective therapeutic
agent.
Our study shows clearly that the predominant effect of
BCG S4-Jena on the bladder cancer cell lines is a reduc-
tion of proliferation that is most likely mediated by apop-
tosis.
Additionally, our data support the hypothesis of Brosch
et al that earlier BCG strains e.g S4-Jena might be supe-
rior therapeutic agent than the now common commer-
cially available strains [21].
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